Snooze alarms may cost you vital sleep — three experts weigh in on the habit
The snooze button has been a common feature of alarm clocks for decades. PeopleImages/iStockphoto/Getty Images via CNN Newsource
When jolted awake by the blare of an alarm clock, it's tempting to reach for the snooze button to catch a bit more shut-eye. In my case, 'just five more minutes' is practically a morning mantra. And what's the harm?
There's increasing debate about your snoozing habit, and whether or not it's silently sabotaging your morning.
On the 'stop snoozing' side of the research, sleep scientist Dr. Rebecca Robbins suggests the snooze alarm may actually cost us sleep.
'That first alarm may interrupt vital stages of sleep, and anything that you might be able to get after hitting the snooze alarm is probably going to be low quality and fragmented sleep,' said Robbins, an associate scientist for the Division of Sleep and Circadian Disorders at Brigham and Women's Hospital.
The average snoozer takes an extra 11 minutes after their first alarm, according to a new study coauthored by Robbins that used data from the sleep-tracking app SleepCycle. That adds up to about one night's worth of sleep per month spent snoozing.
As we sleep, the brain cycles through different stages of neurological activity and the second half of the night is dominated by rapid eye movement (REM) sleep, when most of our dreaming is thought to take place. It's an important sleep stage for our cognitive function and memory consolidation, said Robbins, who is also an assistant professor of medicine at Brigham and Women's Hospital.
'When you press the snooze button, especially for just a few minutes at a time, you're not likely to return to that REM stage,' Robbins said.
But for a different take, there are sleep experts like Dr. Justin Fiala, a pulmonary, critical care and sleep medicine physician at Northwestern Medicine Canning Thoracic Institute.
There isn't consensus on whether this lighter sleep achieved during a snooze session always does more harm than good, said Fiala, who is also an assistant professor at Northwestern Medicine.
On one hand, losing out on quality sleep instead of just waking up later may increase the risk of cognitive impairment and lower one's mood.
'Certainly, if you're feeling worse off (and) more tired from the snooze alarm, I would recommend going back to waking up cold turkey without it,' said Fiala, who also runs the CommunityHealth Chicago sleep clinic.
On the other hand, those with a certain chronotype — a natural disposition determined by factors such as age and genetics — may benefit from the habit, Fiala said, referencing a 2023 study which found night owls tend to rely on their snooze button more.
'If your chronotype is nocturnal, you're a night owl, but your work schedule requires you to be up at 5 a.m., that increases the dissonance between what your body is naturally inclined to do,' Fiala said.
For these night owls, the brief period of light sleep induced by the snooze button may actually help them transition from deeper stages of sleep interrupted by the first alarm into wakefulness, he said, adding that more research should be done to fully understand this effect and its limitations.
Regardless of one's chronotype, this distinction of who gets the most out of snoozing can also help inform how to get the most out of snoozing.
Consistency is key
Most sleep experts emphasize adults get the recommended 7 to 9 hours of sleep per night for good health and emotional well-being. Sleeping enough can also reduce feelings of tiredness upon waking, but the consistency of your sleep timing is just as important as duration, said Kimberly Honn, an associate professor of psychology at Washington State University Spokane.
At deep stages of sleep, electric pulses of the brain reach a highly rhythmic pattern different from our more erratic, awakened state, she explained. Trying to wake up during these stages cuts important brain maintenance processes short and can lead one to experience the foggy effects of sleep inertia, which can last for several minutes or even hours after waking up.
When the body is accustomed to a regular sleep schedule, it may reduce the experience of sleep inertia upon waking, Honn said. The body can grow accustomed to moving through each sleep stage at similar times, ensuring sleep cycles are completed before waking and eventually allowing you to fall asleep faster.
'In the perfect world, we would not be relying on an alarm clock at all,' Robbins said. 'We would be able to fall asleep and wake up naturally and have energy throughout the day.'
Fiala said he generally recommends varying bedtimes by no more than 30 minutes per night, even on weekends. If you have to switch schedules, he says you should change it incrementally over time.
Optimizing your morning routine
It's possible people who use the snooze button less simply don't have the luxury to sleep past their alarm, Robbins suggested.
Inflexible work schedules could require first responders to start their shift promptly, or parents may have to rally their children out the door and toward the school bus.
For this reason, Robbins recommends those trying to ditch a snoozing habit introduce more time constraints into their morning routine by setting the first alarm as late as possible.
'Ask yourself: Is there anything in that morning routine that you could maybe do without? Or maybe you could find a way to do it faster?' Robbins said.
Snoozing could also mean you're losing out on time that could be used for adding wakefulness-promoting habits into your morning routine.
The heaviest snoozers tracked in Robbins' study used around 22 to 27 minutes resting after the first alarm — time that could be used for stretching, journaling or cooking a nutritious breakfast, Robbins suggested.
'We talk a lot about wind down routines and bedtime rituals. I think morning rituals are also really lovely to help you get excited about your day,' Robbins said. 'It's important to find something to look forward to, whether that's a meeting in the morning, making yourself a cup of coffee, whatever helps motivate you (and) gets you out of bed.'
Timing your alarm to the sunrise and allowing natural light to come through your windows in the morning can also help signal your body to wake up, Honn said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
8 hours ago
- CTV News
Shooting leaves 1 dead, 11 hurt on a North Carolina street during a house party
In this image taken from WSOC video, various police and officials gather outside a community after a mass shooting, Sunday, June 1, 2025, in Hickory, a city in Catawba County, N.C. (WSOC via AP) HICKORY, N.C. — Gunfire erupted around a house party in western North Carolina early Sunday and one person was killed and 11 others were hurt, some with gunshot wounds and others with injuries from fleeing the shooting in a usually quiet residential neighborhood, sheriff's deputies said. Authorities said at least 80 shots were fired in the shooting that began at about 12:45 a.m. People reported running, ducking for cover and scrambling to their cars for safety. Hours later Sunday, law enforcement had made no arrests and was seeking tips from the public in the case. A statement from the Catawba County Sheriff's Office said a 58-year-old man, Shawn Patrick Hood, of Lenoir, was killed, the oldest of the victims who ranged in age from as young as 16. It said seven of the injured remained hospitalized late Sunday, though updates on their conditions were not immediately released. One of the victims was previously reported in critical condition. Authorities believe there was more than one shooter, a sheriff's spokesperson said. The agency said it was asking for people who attended the party to contact the office. Sheriff's office Maj. Aaron Turk aid at a news conference that the shooting occurred in a normally quiet neighbhoord in southwest Catawba County about 7 miles (11 kilometers) south of the city of Hickory. He said that about two hours before the shooting, someone in another home complained about noise from the party. He added that deputies responded but that investigators don't believe the noise complaint was the motivation for the shooting. Turk said the crime scene spanned several properties along a neighborhood road, covering about two acres (0.8 hectares), and included outdoor and indoor areas. The North Carolina State Bureau of Investigation and the Hickory Police Department are investigating the shooting. The FBI is also assisting in the case with a specialized evidence response team, officials said.


CTV News
13 hours ago
- CTV News
1 dead, 11 others injured in North Carolina overnight shooting
In this image taken from WSOC video, various police and officials gather outside a community after a mass shooting, Sunday, June 1, 2025, in Hickory, a city in Catawba County, N.C. (WSOC via AP) HICKORY, N.C. — One person is dead and at least 11 others were injured in a mass shooting during a party at a western North Carolina residence, according to the Catawba County Sheriff's Office. The shooting took place at about 12:45 a.m. Sunday in Hickory, a city in Catawba County. One victim is in critical condition and ten others are in serious condition at the hospital, according to the Sheriff's Office. The North Carolina State Bureau of Investigation and the Hickory Police Department are investigating. The Federal Bureau of Investigation is also assisting. No arrests have been made and the number of shots fired is not yet known. The Sheriff's Department has not released the victims' names or ages, but Major Aaron Turk said at a press conference the street is usually quiet. The Associated Press


Globe and Mail
13 hours ago
- Globe and Mail
Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?
The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 to an estimated $381.5 billion by 2033. Two pharmaceutical giants, Eli Lilly (LLY) and Novo Nordisk (NVO), dominate this market. Both companies have created GLP-1 receptor agonists that have transformed obesity treatment: Eli Lilly's Mounjaro (tirzepatide) and Zepbound, and Novo Nordisk's Ozempic and Wegovy (semaglutide). Let's see which company is ahead of the game and has the best investment case right now. The Case for Eli Lilly Stock Valued at $684 billion, Eli Lilly has been a standout performer in the global pharmaceutical industry. Aside from its obesity treatments, it is well-known for developing groundbreaking treatments for autoimmune diseases, cancer, diabetes, Alzheimer's, and other conditions. LLY stock has fallen 6.4% year-to-date, compared to the S&P 500 Index's ($SPX) gain of 0.1%. Recently, Eli Lilly announced that Zepbound has demonstrated superior efficacy in weight loss compared to Novo Nordisk's Wegovy. The SURMOUNT-5 trial found that participants on Zepbound lost more body weight and waist circumference over 18 months than those on Wegovy. This superior efficacy is due to tirzepatide's dual action as a GLP-1 and GIP agonist, which boosts weight-loss effects. Financially, Eli Lilly reported a 45% increase in revenue in the first quarter of 2025, reaching $12.73 billion, thanks to strong sales from Mounjaro and Zepbound. Adjusted earnings increased 29% to $3.34 per share during the quarter. Mounjaro, in particular, saw a 113% year-over-year sales increase to $3.8 billion worldwide. Zepbound's sales increased threefold from the same quarter last year. Aside from the success of its weight-loss drugs, the company's non-incretin portfolio includes successful oncology, neuroscience, and immunology drugs, which are driving growth. The company anticipates 2025 revenue to be in the range of $58 billion to $61 billion, representing year-over-year growth of 28% to 35%. Eli Lilly has taken proactive measures to capitalize on the weight-loss drug boom. The company has handled supply chain issues more effectively than Novo Nordisk, resulting in improved product availability. Last year, the company launched Mounjaro in all major European markets and provided early stage access in China. In order to increase accessibility, the company has formed partnerships with telehealth providers and launched direct-to-consumer initiatives. Furthermore, Lilly's investment in orforglipron, an oral GLP-1 receptor agonist, has yielded encouraging results in Phase 3 studies. Patients lost significant weight, and the convenience of a pill form could transform obesity treatment, making it more accessible and appealing to a larger patient base. On Wall Street, Eli Lilly has earned an overall ' Strong Buy ' rating. Of the 25 analysts who cover the stock, 20 rate it a 'Strong Buy,' two a 'Moderate Buy,' and three recommend a 'Hold.' The average analyst price target of $991.46 suggests a 34.7% increase from current levels. Furthermore, the Street-high estimate of $1,190 implies that the stock could rally by up to 62% over the next year. The Case for Novo Nordisk Stock Valued at $311.7 billion, Novo Nordisk is a Denmark-based pharmaceutical company specializing primarily in diabetes care, obesity treatment, and other chronic disease therapies. Novo Nordisk's Ozempic and Wegovy have been instrumental in the company's growth. However, Eli Lilly's weight loss drugs have demonstrated superior efficacy, challenging Novo Nordisk's market dominance. Novo's stock has fallen nearly 20% year to date, compared to the overall market. In the first quarter of 2025, Novo Nordisk reported earnings per share of 6.53 DKK, in line with analyst expectations. Sales rose 18% year on year to 78.08 billion DKK, led by a 15% rise in Ozempic sales and an 83% increase in Wegovy sales. Despite these gains, the company faces significant challenges due to increased competition and shifting market dynamics. As a result, Novo Nordisk lowered its full-year guidance, projecting 2025 sales growth of 13% to 21%, significantly lower than Lilly's projections. Analysts who cover the stock expect Novo's revenue to grow by 25.5%, followed by earnings growth of 26%. While Eli Lilly's drugs have demonstrated superior efficacy, according to Leerink Partners analyst David Risinger, most people are unaware that Zepbound outperforms Wegovy. As a result, Novo continues to hold 65% of the market, while Lilly holds 34%. However, this may soon change. On Wall Street, Novo Nordisk stock has earned an overall ' Moderate Buy ' rating. Of the 18 analysts who cover the stock, eight rate it a 'Strong Buy,' seven say it is a 'Hold,' one says it is a 'Moderate Sell,' and two suggest a 'Strong Sell.' The average analyst price target of $101.93 suggests a 44% increase from current levels. Furthermore, the Street-high estimate of $160 implies that the stock could rally by up to 128% over the next year. The Verdict: Eli Lilly Takes the Lead Both Eli Lilly and Novo Nordisk continue to strengthen their incretin portfolios. However, based on clinical efficacy, market performance, strategic initiatives, and leadership stability, Eli Lilly currently has a competitive advantage over Novo Nordisk in the weight-loss drug market. Overall, Eli Lilly stock represents a better long-term investment.